A More Precise Description of the AKT2 ‐Related Hypoinsulinemic Hypoglycemia and Overgrowth Syndrome Phenotype, Formerly Described Under the MORFAN Acronym
Authors:
- Marek TurnovecMTMarek Turnovec
- Adéla BubeníkováABAdéla Bubeníková
- OndřEj RýdloOROndřEj Rýdlo
- Petr SkalickýPSPetr Skalický
- Michal ZápotockýMZMichal Zápotocký
- Kryštof HaratekKHKryštof Haratek
- Karolina KočandrlováKKKarolina Kočandrlová
- Milan MacekMMMilan Macek
- Vladimír BenešVBVladimír Beneš
- OndřEj BradáčOBOndřEj Bradáč
- Markéta HavlovicováMHMarkéta Havlovicová
- 23 March 2026
- journal article
- case report
- Published by Wiley in American Journal of Medical Genetics Part A
- p. e70138
Abstract
The AKT2‐related hypoinsulinemic hypoglycemia and overgrowth syndrome was initially described over 30 years ago as MORFAN syndrome which was an acronym for Mental retardation, pre‐ and post‐natal Overgrowth, Remarkable Face, and Acanthosis Nigricans. Despite the limited possibility of confirming a diagnosis on the molecular level at that time, a comprehensive 30‐year follow‐up of a patient facilitated a detailed exploration of the syndrome's clinical trajectory. This article presents a case report spanning three decades, highlighting the significance of detailed clinical follow‐up in understanding and studying this unique syndrome. Although initially associated with intellectual deficiency, the patient's intellectual abilities remain largely within the normal range. Neuropsychological examinations revealed selective neurocognitive impairment, with a predominant disruption in psychomotor speed and executive functions. Molecular genetic examination confirmed a pathogenic variant in the AKT2 gene, associated with impaired insulin metabolism and increased tumorigenesis risk. Neurooncological assessments revealed intracranial meningiomatosis, emphasizing the syndrome's potential oncological implications. Surgical interventions addressed various complications, including meningiomas and renal hamartomas. The presented case offers valuable insights into the long‐term natural history of AKT2‐related hypoinsulinemic hypoglycemia and overgrowth syndrome, suggesting the importance of regular oncological surveillance due to its predisposition to tumorigenesis, thereby providing clinical considerations for future cases based on long‐term follow‐up experience.Keywords
Funding Information
- Ministerstvo Zdravotnictví Ceské Republiky (64203)
- Ministerstvo Zdravotnictví Ceské Republiky (NU21‐07‐00419)
This publication has 17 references indexed in Scilit:
- CircPTK2 accelerates tumorigenesis of colorectal cancer by upregulating AKT2 expression via miR‐506‐3pThe Kaohsiung Journal of Medical Sciences, 2022
- Facial Dysmorphic Features in a Patient With Nonketotic Hypoglycemia and a Pathogenic Variant in the AKT2 GeneAACE Clinical Case Reports, 2021
- The Musculoskeletal Manifestations of Marfan Syndrome: Diagnosis, Impact, and ManagementCurrent Rheumatology Reports, 2021
- Pathophysiology and Pathogenesis of Marfan Syndrome2021
- Association between AKT2 gene polymorphism and polycystic ovary syndrome: a case-control studyGynecological Endocrinology, 2021
- MORFAN Syndrome: An Infantile Hypoinsulinemic Hypoketotic Hypoglycemia Due to an AKT2 MutationThe Journal of Pediatrics, 2015
- AKT2 expression in histopathologic grading and recurrence of meningiomasEuropean Journal of Surgical Oncology, 2014
- An Activating Mutation of AKT2 and Human HypoglycemiaScience, 2011
- Akt2 and Akt3 play a pivotal role in malignant gliomasNeuro-Oncology, 2009
- Morfan: A new syndrome characterized by mental retardation, pre‐ and postnatal overgrowth, remarkable face and acanthosis nigricans in 5‐year‐old boyAmerican Journal of Medical Genetics, 1993